No Data
No Data
Huahai Pharmaceutical's Unit Gets Registration Nod for Levetiracetam Oral Solution
Zhejiang Huahai Pharmaceutical (600521.SH): Registration certificate obtained for pharmaceutical oral solution of levetiracetam.
On July 19, Gelun Hui reported that its subsidiary, Changxing Pharmaceutical Co., Ltd., received the Drug Registration Certificate issued by the National Medical Products Administration (NMPA) for oral solution of Levetiracetam. The oral solution is mainly used as an adjunctive treatment for partial seizures in adult, pediatric and infants over one month old with epilepsy.
Huahai Pharmaceutical Gets Nod to Register Quetiapine Fumarate Tablets
Express News | With innovation and internationalization, nearly 60% of the performance of 92 biomedical companies in the first half of the year exceeded expectations.
Zhejiang Huahai Pharmaceutical Subsidiaries Get Regulatory Nod for Tumor Clinical Trial; Shares Down 3%
Express News | Zhejiang Huahai Pharmaceutical: Notice of Approval of Clinical Trial Batch for HB0046 Injection
No Data